2011
Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer
Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: 181-188. PMID: 21549517, DOI: 10.1016/j.ijrobp.2010.05.006.Peer-Reviewed Original ResearchConceptsSingle-fraction stereotactic body radiotherapyAdvanced pancreatic cancerSequential gemcitabinePancreatic cancerGrade 3Local controlIntensity-modulated radiotherapy techniqueStereotactic body radiation therapyGreater nonhematologic toxicityLate grade 3Nonmetastatic pancreatic adenocarcinomaAcute grade 3Cycles of chemotherapyFraction Stereotactic Body Radiation TherapyExcellent local controlPhase II trialStereotactic body radiotherapyBody radiation therapyInternal target volumeInstitutional review boardNonhematologic toxicityAlive patientsII trialLocal progressionDuodenal perforation
2009
Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Kunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.Peer-Reviewed Original ResearchStanford Cancer CenterGastroesophageal junction cancerMetastatic gastricJunction cancerRetrospective reviewPossible treatment-related deathSingle-institution retrospective reviewCarboplatin AUC 6Regimen of carboplatinCycles of chemotherapyMedian overall survivalTreatment-related deathsStandard chemotherapy regimenFourty-five patientsGastroesophageal junction adenocarcinomaFluoropyrimidine-based treatmentSignet ring featuresAUC 6Chemotherapy-naïvePo bidChemotherapy regimenOnly patientsOverall survivalJunction adenocarcinomaMedian age